Michael Volk, MD, University of
Michigan, Ann Arbor,
Michigan, and colleagues obtained data of new patient prescriptions for pegylated interferon alfa-2a and -2b (Pegasys and Peg Intron, respectively) filled between 2002 to 2007.
Results of the prescription audit showed there were 126,000 new prescriptions for pegylated interferon products in 2002 and by 2007 that figured declined to 83,000 prescriptions.
Researchers project fewer than 1.